Header
TRIALS
 
Search Website
GO
Open to recruitment
 
ACED

Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone.

Summary

To explore whether the addition of oral acetazolamide allows for dexamethasone dose reduction without clinical deterioration in performance status in the management of raised intracranial pressure in recurrent and/or progressive High Grade Glioma (HGG).

Study Chair
 
Professor Meera Agar 
c/o COGNO Coordinating Centre

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: aced@ctc.usyd.edu.au

Trial Status: Open to recruitment
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information
 
 
 
VERTU

A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT).

Summary

To evaluate the combination of the PARP inhibitor veliparib with radiotherapy and adjuvant temozolomide to improve progression-free and survival outcomes of GBM patients with unmethylated MGMT.

Study Chair / COGNO CTC Clinical Lead
 
Dr Mustafa Khasraw
c/o COGNO Coordinating Centre

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: vertu@ctc.usyd.edu.au

Trial Status: Open to recruitment
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information
 
 
 
Closed to recruitment

CABARET

A randomised phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme.

Summary

To determine the effect of the combination of bevacizumab plus carboplatin versus bevacizumab alone on progression-free survival (using modified RANO criteria) in patients with recurrent grade IV glioma (glioblastoma multiforme).

Study Chair
 
Dr Kathryn Field
c/o COGNO Coordinating Centre

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: cabaret@ctc.usyd.edu.au

Trial Status: Closed to recruitment

For the trial result summary, please click here.
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information
 
 
 
CATNON

Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.

Summary

The main purpose of this study is to determine whether chemotherapy given in addition to radiotherapy or the addition of chemotherapy after the completion of radiotherapy will improve overall survival and the time until tumour progression. Further, this study aims to find out the effects of chemotherapy when either given at the same time as radiotherapy or after finishing radiotherapy. The second major objective is to identify patients most likely to benefit from this specific treatment based on molecular markers analysed on the tumour specimen previously resected which will ultimately allow the development of new treatments more specific for each patients tumour characteristics.

Study Chair

A/Prof Anna Nowak
School of Medicine and Pharmacology
Sir Charles Gairdner Hospital
4th Floor, G block
Hospital Ave
Nedlands
WA 6009

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: catnon@ctc.usyd.edu.au

Trial Status: Closed to recruitment
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information
 
  
 

SEED

Self-reported evaluation of the adverse effects of dexamethasone.

Summary

This is not an interventional study but a feasibility study measuring patient reported outcomes (PROs) in the evaluation of side effects and toxicities from steroid use in patients with brain tumours or brain metastases or advanced cancer.  A multicentre cohort study with patient (including PRO measures), caregiver and clinician measures. Data will inform the baseline measures for a clinical study that will investigate whether acetazolomide, a steroid sparing agent can reduce the need for steroids and therefore reduce the side effects associated with steroid use.

Study Chair
 
Dr Meera Agar
Braeside Hospital
Dept of Palliative Care
340 Prairievale Road
Prairiewood
NSW 2164

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: seed@ctc.usyd.edu.au

Trial Status: Closed to recruitment
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information
 
  
 
Closed

Temozolomide/Caelyx

Phase II Trial of Temozolomide and Caelyx in the Treatment of Patients with Glioblastoma Multiforme following concurrent radiotherapy and chemotherapy.

Summary

Phase II Trial of six months of oral Temozolomide (200mg/m2 days 1-5, 4 weekly) and intravenous liposomal doxorubicin (40mg/m2 4 weekly) (Caelyx) in standard doses in the Treatment of Patients with Glioblastoma Multiforme (GBM) following concurrent radiotherapy and chemotherapy to improve six month progression free survival. The purpose of the study is to evaluate the efficacy and toxicity of combination Temozolomide and Caelyx in patients with GBM following concurrent radiotherapy and chemotherapy.

Study Chair

Prof Mark Rosenthal
Royal Melbourne Hospital
Grattan Street
Parkville
Victoria
Australia 3050

Coordinating Centre

COGNO
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: cogno@ctc.usyd.edu.au

Trial Status: Closed
 
Please refer to the Australian and New Zealand Clinical Trials Registry (ANZCTR) for additional information